HIOC

HIOC
Clinical data
ATC code	None;
Identifiers
	IUPAC name N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-2-oxo-3-piperidinecarboxamide;
CAS Number	314054-36-9;
PubChem CID	5012758;
ChemSpider	4192105;
UNII	JC3KZQ72GW;
CompTox Dashboard (EPA)	DTXSID401032115 ;
Chemical and physical data
Formula	C16H19N3O3
Molar mass	301.346 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc2c(cc1O)c(c[nH]2)CCNC(=O)C3CCCNC3=O;
	InChI InChI=1S/C16H19N3O3/c20-11-3-4-14-13(8-11)10(9-19-14)5-7-18-16(22)12-2-1-6-17-15(12)21/h3-4,8-9,12,19-20H,1-2,5-7H2,(H,17,21)(H,18,22); Key:ZIMKJLALTRLXJO-UHFFFAOYSA-N;

HIOC is a small-molecule agent which acts as a selective TrkB receptor agonist (active at at least 100 nM; prominent activation at 500 nM).^[1]^[2]^[3] It was derived from N-acetylserotonin (NAS).^[2]^[3]^[4] Relative to NAS, HIOC possesses greater potency and a longer half-life (~30 min or less for NAS in rats, while HIOC is still detectable up to 24 hours after administration to mice; ~4 hour half-life for HIOC in mouse brain tissues).^[2]^[3] It is described as producing long-lasting activation of the TrkB receptor and downstream signaling kinases associated with the receptor.^[2] HIOC is systemically active and is able to penetrate the blood-brain-barrier.^[2] In animal studies, HIOC was found to robustly protect against glutamate-induced excitotoxicity, an action which was TrkB-dependent.^[3]